The objective of this study was to investigate the relationship between molecular epidemiology and antibiotic susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) over a period of 4 years. The antibiotype of all MRSA isolates that were identified during a yearly period of 3 months was determined; 50 consecutive non-replicate MRSA isolates were typed each year. Susceptibility rates to gentamicin, tobramycin and ofloxacin remained stable (95, 16 and 4 %, respectively). In contrast, the proportion of MRSA isolates susceptible to erythromycin increased progressively from 10·5 to 32·5 % (P , 0·001). PFGE analysis of genomic DNA from 200 isolates revealed the presence of 15 different clones. Two epidemic clones were identified, which contained 150 (clone A) and 28 (clone C) isolates. Non-epidemic strains were more frequently susceptible to ofloxacin (31·8 versus 1·1 %) and tobramycin (45·4 versus 16·8 %) than epidemic strains; those isolates that were susceptible to all antibiotics tested belonged to sporadic clones. The increase of erythromycin susceptibility within MRSA isolates was caused by the emergence of clone C. This study suggests that when selection pressure exerted by an antibiotic is insufficient (i.e. below a threshold level), fitness advantages play a predominant role in the dissemination of MRSA clones. The balance between the selection pressure exerted by antibiotics and the disadvantage of lower replication rates of resistant strains in the absence of antibiotics complicates the biological model of clonal dissemination of epidemic MRSA strains.
INTRODUCTION
Over the last four decades, methicillin-resistant Staphylococcus aureus (MRSA) has spread throughout the world and become highly endemic in many geographical areas. This pathogen causes severe morbidity and mortality in hospitals worldwide (Boyce, 1990; Voss et al., 1994; Aubry-Damon et al., 1997; Bertrand et al., 2000) . In France, 30-40 % of S. aureus strains are methicillin-resistant and the incidence of MRSA isolated from clinical specimens ranges from 0·04 to 3·6 per 1000 hospital-days, according to the hospital. The overall incidence of MRSA is approximately 0·8 per 1000 hospital-days (Albertini et al., 2002) . All MRSA strains isolated before 1990 were homogeneously resistant to methicillin and also resistant to an increasing number of major classes of antibiotics, including aminoglycosides, fluoroquinolones and macrolides. In 1991, gentamicin-susceptible (GS) MRSA clones emerged in a number of Parisian hospitals (Aubry-Damon et al., 1997; Lemaître et al., 1998) and subsequently spread to our region in eastern France in 1994 (Bertrand et al., 2000) . In our hospital, the prevalence of tobramycin-and amikacin-susceptible MRSA has increased since 1996 (Talon et al., 2002) and the prevalence of erythromycin-susceptible MRSA has increased since 1998. Nowadays, it is common for MRSA isolates to be susceptible to all non-â-lactam antibiotics tested (except fluoroquinolones).
To improve our understanding of changes in MRSA susceptibility to non-â-lactam antibiotics, we evaluated the relationship between antibiotic susceptibility and MRSA genotype over a 4-year period. For this purpose, we used PFGE as an epidemiological tool. In 1994, our infection-control committee made the control of MRSA a major priority. An MRSA control programme was implemented progressively in all high-risk units. Since 1997, 14 of the 59 units (corresponding to all high-risk departments, including the adult intensive-care units and the septic surgical unit) have been following this programme. The control strategy is based on screening for MRSA on admission: nasal fluid samples are obtained by using sterile cotton swabs from all patients on admission. In the first 48 h after admission, before the results of the screening cultures are available, patients are considered to be positive for MRSA and kept in isolation. Patients who are actually positive for MRSA are then given nasal mupirocin. All MRSA-positive patients are kept in individual rooms or in cohorts. Special precautions are taken to prevent cross-contamination, including the use of disposable gowns and gloves, hand-washing, alcohol hand-rubbing and the implementation of strict environmental hygiene measures. These procedures are also applied to patients in low-risk departments who give clinical samples that test positive for MRSA, who are not screened on admission. The programme does not include any restrictions on antibiotic use.
METHODS
Bacterial isolates. Since 1999, our hospital has participated in an MRSA surveillance network. This network carries out annual 3-month studies (April-June). During this period, all MRSA strains that were isolated for diagnostic purposes (excluding surveillance specimens) from patients hospitalized for .24 h were collected and kept at À73 8C. When multiple MRSA isolates were obtained from the same patient, only the first isolate was included; duplicate isolates were excluded.
Antimicrobial agent susceptibility testing. The antibiotype of all MRSA isolates identified during the surveillance periods was determined. Antibiotic susceptibility was determined by the disc-diffusion method on Mueller-Hinton agar with the following discs (Bio-Rad): gentamicin (10 IU), tobramycin (10 ìg), kanamycin (30 IU), erythromycin (15 IU), clindamycin (2 IU), pristinamycin (15 ìg), ofloxacin (5 ìg), fusidic acid (10 ìg) and rifampicin (30 ìg). Isolates were classified as susceptible, intermediate or resistant, according to the criteria of the Antibiogram Committee of the French Society for Microbiology (Soussy et al., 2000) . Oxacillin resistance was tested by incubating isolates with a 5 ìg oxacillin disc at 30 8C for 48 h. Susceptibility to glycopeptides was tested by spotting 10 ìl suspension that contained 10 6 c.f.u. ml À1 onto Mueller-Hinton agar (Bio-Rad) plates that contained 4 or 16 mg teicoplanin l À1 .
Molecular typing. Fifty consecutive, non-replicate isolates that were collected each year during the study period (of 280-300 MRSA recovered per year, excluding surveillance samples) were typed. The macrorestriction pattern of total DNA was determined by PFGE (CHEF-DR III; Bio-Rad) using SmaI, as described previously by Prevost et al. (1992) . GelCompar software (Applied Maths) was used to establish a DNA similarity matrix based on the Dice coefficient (232 strain comparisons). A dendrogram was constructed by using the UPGMA clustering method with the Dice coefficient. To ensure that the gels were comparable, S. aureus NCTC 8325 was included as a reference strain.
Isolates with indistinguishable PFGE patterns were assigned to the same clone and clonal variant. Strains that differed by up to (and including) six bands were considered to belong to different clonal variants; strains that differed by more than six bands were considered to belong to different clones (Tenover et al., 1995) . Clones and clonal variants were designated by letters and by numbers in suffix, respectively.
Antibiotic use. Annual quantities of antibiotics delivered to each unit during the study period were collected from the pharmacy information system. Grams and international units of antimicrobials were further converted into defined daily doses (DDDs) (Natsch et al., 1998) . Table 1 reports the frequency of MRSA in our hospital since 1994, based on data collected as part of the MRSA surveillance programme (1999) (2000) (2001) (2002) . Data collected in 1994 and 1998 were obtained with the same methodology.
RESULTS

MRSA endemicity
Susceptibility to antimicrobials
Pooled data for the last 4 years (Table 2) show that since 1999, 95 % of MRSA isolates in our hospital were gentamicinsusceptible and that approximately 15 % of MRSA isolates were susceptible to tobramycin. The proportion of MRSA susceptible to erythromycin increased significantly and progressively from 7·0 to 32·5 % during the study period (P , 0·001). In contrast, the isolates remained resistant to ofloxacin and susceptible to rifampicin and fusidic acid.
No isolates exhibited reduced susceptibility to teicoplanin (MIC . 4 mg l À1 ).
Despite the change in antibiotic-resistance patterns in MRSA, when four antimicrobial agents (gentamicin, tobramycin, erythromycin and ofloxacin) were used as phenotypic markers, 61·4 % of MRSA isolates displayed the major antibiotype (1d) ( Table 3 ). Approximately one-sixth (15·4 %) of the isolates belonged to antibiotype 1c and 12·8 % belonged to antibiotype 2d.
Molecular typing
PFGE analysis of genomic DNA from 200 isolates revealed 15 different clones. Two epidemic clones were identified, which contained 150 (clone A) and 28 (clone C) isolates (Fig. 1) . Four other clones that contained two, two, four and five isolates were called micro-epidemic, and nine sporadic clones each contained a single isolate. Clone A was divided Lemaître et al. (1998) ] and three strains that belong to the major clone in our region, which were isolated in 1998 (Bertrand et al., 2000) . Clone C also included an isolate collected in Pitié-Salpêtrière Hospital in 1991 [called clone C by Lemaître et al. (1998) ]. Clone C was not isolated in our hospital in 1998 (Bertrand et al., 2000) ; it was first detected in our hospital in 1999 and accounted for 22 % of MRSA in 2002 (Table 4 ). The proportion of MRSA isolates that belonged to clone A decreased progressively during the study period (from 86 to 66 %). The frequency of non-epidemic isolates remained stable (10-12 %). However, the overall incidence of MRSA in our hospital increased slightly in 2001-2002 (Table 1) .
Association between antibiotic susceptibility and genotype
Association between clone and antibiotype is reported in Table 4 . Non-epidemic strains were more frequently suscep- tible to ofloxacin and tobramycin than epidemic clones. The four isolates that were susceptible to all antibiotics tested belonged to sporadic clones. Nine of the ten gentamicinresistant (GR) MRSA isolates belonged to epidemic clones (eight to clone A and one to clone C) and were not related to the epidemic GR-MRSA clones that were present in our hospital in the early 1990s (data not shown). Moreover, the eight isolates clustered in the major epidemic clone were distributed between seven clonal variants. Both epidemic and non-epidemic strains were susceptible to tobramycin; tobramycin-susceptible isolates were distributed in numerous clonal variants of the epidemic clones. The increase in erythromycin susceptibility was caused by the wide-scale dissemination of clone C. Indeed, erythromycin-susceptible MRSA remained very rare in clone A (4 %) but accounted for 78·6 % of isolates in clone C. Moreover, the frequency of erythromycin susceptibility increased in clone C during the study period: 20, 60 and 90·9 % in 2000, 2001 and 2002 , respectively. Lemaître et al., 1998; Lelièvre et al., 1999; Bertrand et al., 2000; Galdbart et al., 2000) .
Antibiotic use
The proportion of MRSA isolates that is susceptible to gentamicin increased dramatically between 1994 and 1998 (Bertrand et al., 2000) . Currently, 95 % of MRSA isolates from our hospital are gentamicin-susceptible (GS-MRSA). Several reports support the hypothesis that GS-MRSA reemerged due to the spread of GR-MRSA clones in which the aac69-aph299 gene had been excised or deleted (Lemaître et al., 1998; Lelièvre et al., 1999; Blanc et al., 2001) . The fitness of these clones probably increased during their evolution, giving them an advantage over other clones. Experiments in vitro have shown that GS-MRSA isolates grow more rapidly than GR-MRSA isolates, thus giving them a competitive advantage (Bertrand et al., 2000; Laurent et al., 2001) . The switch from GR-to GS-MRSA clones has been attributed to changes in antibiotic use (Aubry-Damon et al., 1997; Lelièvre et al., 1999) . However, this hypothesis has not been confirmed and aminoglycoside use does not appear to play a major role in the dissemination of GS-MRSA strains (Bertrand et al., 2000; Blanc et al., 2001 ). In 1998, clone A was divided into seven clonal variants and did not include GR-MRSA. In our study, the genomic diversity within this clone appeared to be greater (28 clonal variants). The presence of GR-MRSA in this clone does not reflect the reemergence of ancestral clones but merely the evolution of GS-MRSA through the acquisition of a gene (perhaps from coagulase-negative staphylococci) that confers resistance to gentamicin.
Tobramycin-susceptible MRSA isolates were rare until 1998 (Bertrand et al., 2000) but became more frequent in 1999 (Talon et al., 2002) . Susceptibility to tobramycin appears to be a phenotypic variation among MRSA isolates. The unpredictability of this modification is supported by the fact that it occurred within various clones and clonal variants, regardless of their epidemic nature. This modification did (1) 23·1 (3) 44·4 (4) not confer any advantages in terms of fitness (Bertrand et al., 2000) . The emergence of tobramycin susceptibility within MRSA does not seem to be related to variations in aminoglycoside use. Indeed, it emerged in parallel in various settings, even though the selective pressure exerted by aminoglycosides was considerably different (Talon et al., 2002) .
The increased frequency of erythromycin susceptibility among MRSA isolates was due to the dissemination of a new clone (C) in our hospital. This clone was described by Lemaître et al. (1998) as being a minor clone that was present in a Parisian hospital in 1992. The frequency of clone C in this hospital increased considerably between 1992 and 1996. This clone, which was probably introduced into our hospital via a transferred patient, presented a similar epidemiology in our hospital 8 years later. Thus, the evolution of erythromycin susceptibility among MRSA isolates is a strong marker of the dissemination of clone C. This surveillance is particularly important because it seems that clone C disseminates without competing with the major epidemic clone, A. The emergence of clone C was probably responsible for the slight increase in MRSA incidence in our hospital that was first observed in 2001 and confirmed in 2002, although the incidence of MRSA had been decreasing since the MRSA control programme was initiated in 1994 (Bailly et al., 1999; Bertrand et al., 2000) .
In our hospital, there were no restrictions on antibiotic use. During the study period, no significant variations in antibiotic usage occurred (Table 5) . â-Lactams and fluoroquinolones accounted for 71·8 and 13·9 %, respectively, of all antibiotics used. Thus, these two classes of antimicrobial exerted considerable selection pressure for resistant bacteria such as MRSA. It is noteworthy that the ofloxacin susceptibility level remains extremely low in our hospital; the loss of ofloxacin resistance seems to prevent the dissemination of such strains (Table 4 ). It is possible that when the selection pressure exerted by an antibiotic is insufficient (i.e. below a threshold level), fitness advantages play a predominant role in the dissemination of MRSA clones. Therefore, the concept of 'total use threshold', introduced by Levy (1994) , appears to be an important factor in the antibiotic-resistance changes in epidemic MRSA. In our case, the use of aminoglycosides and macrolides (3·7 and 5·0 % of total antibiotic use, respectively) was below this threshold, thus variations in use of both antibiotics did not affect the evolution of the MRSA susceptibility pattern.
In other countries such as Germany (Witte et al., 2001) , Finland (Salmenlinna & Vuopio-Varkila, 2001 ), Greece (Polyzou et al., 2001; Pournaras et al., 2001) and Australia (Torvaldsen et al., 1999) , a similar trend of emergence and spread of MRSA with susceptibility to aminoglycosides, macrolides and other antibiotics has been observed.
The spread of a new epidemic MRSA clone in our hospital is a matter of concern because it could reverse the downward trend of MRSA incidence observed since 1994. At a practical clinical level, continuing evolution of MRSA provides an opportunity for the controlled reintroduction of antibiotics (particularly aminoglycosides) in anti-MRSA therapies, meaning that we would no longer be reliant on glycopeptides. The balance between selection pressure exerted by antibiotics and the disadvantage of lower replication rates of resistant strains in the absence of antibiotics complicates the biological model of the clonal dissemination of epidemic MRSA strains. Further studies, including in vitro fitness analysis and epidemiological surveys, should be undertaken to determine the relative effects of antibiotic use and bacterial fitness on MRSA epidemiology. 
